Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series

Slodownik, Dan; Levi, Assi; Lapidoth, Moshe; Moshe, Shlomo

doi:10.1159/000524380

Cited by 8 publications

(3 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACD mechanisms are highly variable and allergen-specific with, e.g., a strong Th1/Th17-polarization found for nickel while fragrances and rubber showed a Th2-bias [ 42 ]. Records found for a total of 67 patients with or without concomitant AD that were refractory to topical and systemic steroids as well as other systemic immunosuppressants and subsequently treated with dupilumab showed complete or partial responses in 65/67 patients ( Table 1 ) [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. In two cases, no effects of dupilumab were reported [ 60 , 61 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…55,56,58,59 Dupilumab has also shown to be effective in ACD as well as for nonatopic causes of hand eczema such as occupational ICD. [60][61][62][63] The most frequent AEs reported were nasopharyngitis and headaches, and skin infections were found to be more frequent in the placebo group. 54 Dupilumab-induced ocular surface disease is another important consideration for dermatologists as it has been shown to be more frequent in patients with AD when compared to patients with asthma, chronic rhinosinusitis with nasal polyps, or eosinophilic esophagitis.…”

Section: Il-4/il-13 Inhibitorsmentioning

confidence: 99%

A Review of Existing and New Treatments for the Management of Hand Eczema

Molin

2023

J Cutan Med Surg

View full text Add to dashboard Cite

Hand eczema is a chronic condition that affects an estimated 14.5% of the general population. It has severe quality of life ramifications in those that struggle with it, including days missed from work or school, productivity loss and impaired work functioning. For years, the standard of care included topical moisturizing creams, topical steroids and more recently systemic agents. As new therapeutic targets emerge and recent advances are being developed, it is now more possible than ever that hand eczema can be managed via the underlying mechanisms. A review of the literature was conducted to identify current treatment options for hand eczema and chronic hand eczema. The terms ‘hand eczema’, ‘hand dermatitis’ were used to search PubMed, CENTRAL and Embase. To identify new therapies still undergoing investigation, we used the terms ‘hand eczema’, ‘hand dermatitis’, ‘atopic dermatitis’, and ‘vesicular eczema of hands and/or feet’ to search Clinicaltrials.gov for all studies until December 2022. There were 56 ongoing clinical trials identified for pharmacological treatments for hand eczema on Clinicaltrials.gov from 2000 - 2022, with 16 that are new or ongoing. These included studies for dupilumab, ruxolitinib, delgocitinib (LEO124249), gusacitinib (ASN002), AFX 5931, and roflumilast (ARQ-252). Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician’s management toolbox for patients with hand eczema.

show abstract

“…A patient with Ni-atopic occupational chronic contact dermatitis failed to execute remission under various systemic modalities. Dupilumab treatment for six months resulted in complete remission for the first time in the last five years [ 119 ]. A patient with severe Cr-induced ACD with multiple scaly, erythematous plaques scattered over the skin of his hands, head, and neck was successfully treated with dupilumab because of refractory to topical corticosteroids [ 120 ].…”

Section: Treatment With Biologicalsmentioning

confidence: 99%

Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants

Zemelka‐Wiącek¹

2022

JCM

View full text Add to dashboard Cite

Metal allergy is mainly an environmental disorder which can cause allergic contact dermatitis. Environmental metal exposures include jewelry, everyday metal items, mobile phones, leather, metal-rich food and implants, including stents or anchors. While consumer exposure is liable for the majority of metal hypersensitivity cases, the significance of occupational exposure to metals remains relevant. Although the most common metal allergens are nickel, chromium, and cobalt; however, lately, gold, palladium, titanium, and some others have also attracted attention. This review highlights advances in metal allergy mechanisms, biomarkers for potential patients’ stratification as well as biological treatments. The most recent evidence of human exposure to metal for risk assessment is discussed, as well as the relationship between the occurrence of metal hypersensitivity and implanted devices, including non-characteristic symptoms. The latest data on the diagnosis of metal hypersensitivity are also reported.

show abstract

Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series

Cited by 8 publications

References 18 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

A Review of Existing and New Treatments for the Management of Hand Eczema

Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants

Contact Info

Product

Resources

About